Research

Kovalik V, Sardi A, Falla-Zuniga LF, Wasti A, King MC, Iugai S, Uzhegova K, Nieroda C, Montes TD, Gushchin V. Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2026 Mar 2. doi: 10.1245/s10434-025-19059-x. Epub ahead of print. PMID: 41772250 . What was this study about? This study looked at the financial challenges (often called “financial toxicity”) experienced by people undergoing cytoreductive surgery

Somashekhar, S.P. HIPEC in Advanced Ovarian Cancer: From Controversy to Contextual Standard of Care. Indian J Gynecol Oncolog 24 , 52 (2026). https://doi.org/10.1007/s40944-026-01122-4 What is this study about? This article looks at a treatment approach called HIPEC (hyperthermic intraperitoneal chemotherapy) for people with advanced ovarian cancer—a cancer that often spreads within the abdomen. Even with surgery and chemotherapy, many patients still have tiny cancer cells l

Al Mahrizi, A.D., Mossolem, F., Major, E. et al. Prophylactic Intraperitoneal Chemotherapy with Platinum Agents Following Curative Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 33 , 2972–2984 (2026). https://doi.org/10.1245/s10434-025-18903-4 What is this study about? This research looked at a strategy to help prevent colorectal (colon and rectal) cancer from coming back after surgery. Even when surgery successfully removes all visib

A quarterly newsletter with the latest news, views and announcements from Peritoneal Surface Oncology Group International (PSOGI) Led by pioneering surgical oncologist Dr. Paul Sugarbaker, PSOGI is a collaboration of experts from around the world on the treatment of peritoneal cancer and is dedicated to improving treatment and survival of patients with peritoneal metastases . We are proud to share their quarterly newsletter. This newsletter highlights new research on cancers